TABLE 1 from Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC | Synapse
March 14, 2024Open Access
TABLE 1 from Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Baseline characteristics of patients with ALK-positive NSCLC in clinical cohort by EML4-ALK v1 and v3 subgroups